AptaBio Therapeutics Inc. (293780.KQ)
KRW 7660.0
(-1.67%)
KRW 7660.0
(-1.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -12.06 Billion KRW | -80.77% |
| 2022 | -10.56 Billion KRW | 1.16% |
| 2021 | -10.68 Billion KRW | -172.76% |
| 2020 | -3.91 Billion KRW | 37.78% |
| 2019 | -6.29 Billion KRW | -55.01% |
| 2018 | -4.06 Billion KRW | -106.69% |
| 2017 | -1.96 Billion KRW | -132.71% |
| 2016 | -844.74 Million KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -7.03 Billion KRW | -77.29% |
| 2024 Q1 | -3.96 Billion KRW | 52.25% |
| 2023 Q2 | -2.15 Billion KRW | 51.84% |
| 2023 Q3 | -4.16 Billion KRW | -93.74% |
| 2023 Q4 | -8.3 Billion KRW | -99.26% |
| 2023 Q1 | -4.46 Billion KRW | -74.08% |
| 2023 FY | -19.09 Billion KRW | -80.77% |
| 2022 FY | -10.56 Billion KRW | 1.16% |
| 2022 Q4 | -2.56 Billion KRW | 44.36% |
| 2022 Q3 | -4.61 Billion KRW | -36.32% |
| 2022 Q2 | -3.38 Billion KRW | -30.16% |
| 2022 Q1 | -2.6 Billion KRW | -11.05% |
| 2021 FY | -10.68 Billion KRW | -172.76% |
| 2021 Q3 | -3.11 Billion KRW | -49.62% |
| 2021 Q2 | -2.07 Billion KRW | 34.15% |
| 2021 Q1 | -3.15 Billion KRW | -54.73% |
| 2021 Q4 | -2.34 Billion KRW | 24.74% |
| 2020 Q1 | -889.66 Million KRW | 54.42% |
| 2020 Q4 | -2.04 Billion KRW | -224.81% |
| 2020 FY | -3.91 Billion KRW | 37.78% |
| 2020 Q3 | -628.27 Million KRW | -74.39% |
| 2020 Q2 | -360.27 Million KRW | 59.5% |
| 2019 Q4 | -1.95 Billion KRW | -6.27% |
| 2019 FY | -6.29 Billion KRW | -55.01% |
| 2019 Q3 | -1.83 Billion KRW | -157.55% |
| 2019 Q2 | -713.09 Million KRW | 0.0% |
| 2018 Q4 | -2.28 Billion KRW | -672.57% |
| 2018 Q3 | 399.88 Million KRW | 127.39% |
| 2018 Q2 | -1.46 Billion KRW | 0.0% |
| 2018 FY | -4.06 Billion KRW | -106.69% |
| 2017 FY | -1.96 Billion KRW | -132.71% |
| 2016 FY | -844.74 Million KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.42 Billion KRW | 37.914% |
| CMG Pharmaceutical Co., Ltd. | 6.45 Billion KRW | 286.847% |
| Celltrion Pharm, Inc. | 21.26 Billion KRW | 156.721% |
| Huons Global Co., Ltd. | 38.38 Billion KRW | 131.424% |
| DongKook Pharmaceutical Co., Ltd. | 47.17 Billion KRW | 125.568% |
| Enzychem Lifesciences Corporation | -9.32 Billion KRW | -29.328% |
| Humedix Co., Ltd. | 24.82 Billion KRW | 148.595% |
| Boditech Med Inc. | 25.94 Billion KRW | 146.486% |
| EuBiologics Co., Ltd. | -13.87 Billion KRW | 13.094% |
| FutureChem Co.,Ltd | -6.7 Billion KRW | -79.785% |
| Huons Co., Ltd. | 50.47 Billion KRW | 123.897% |
| BNC Korea Co., Ltd. | 25.68 Billion KRW | 146.958% |